Natera, Inc. (NASDAQ:NTRA – Get Free Report) CEO Steven Leonard Chapman sold 5,838 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $204.14, for a total transaction of $1,191,769.32. Following the transaction, the chief executive officer owned 150,769 shares of the company’s stock, valued at approximately $30,777,983.66. This represents a 3.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Steven Leonard Chapman also recently made the following trade(s):
- On Tuesday, March 10th, Steven Leonard Chapman sold 5,623 shares of Natera stock. The stock was sold at an average price of $204.13, for a total transaction of $1,147,822.99.
- On Monday, March 2nd, Steven Leonard Chapman sold 3,950 shares of Natera stock. The stock was sold at an average price of $200.02, for a total transaction of $790,079.00.
- On Tuesday, February 3rd, Steven Leonard Chapman sold 4,725 shares of Natera stock. The stock was sold at an average price of $230.77, for a total transaction of $1,090,388.25.
- On Monday, February 2nd, Steven Leonard Chapman sold 85,299 shares of Natera stock. The stock was sold at an average price of $230.72, for a total transaction of $19,680,185.28.
Natera Trading Down 2.7%
NTRA traded down $5.42 during trading on Wednesday, reaching $194.75. 963,644 shares of the company’s stock were exchanged, compared to its average volume of 1,219,699. Natera, Inc. has a one year low of $131.81 and a one year high of $256.36. The stock has a market capitalization of $27.71 billion, a PE ratio of -127.29 and a beta of 1.68. The firm has a fifty day moving average price of $202.22 and a two-hundred day moving average price of $213.80.
Institutional Investors Weigh In On Natera
A number of institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. boosted its stake in shares of Natera by 10.5% in the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after purchasing an additional 1,225,420 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after purchasing an additional 2,420,263 shares during the last quarter. State Street Corp boosted its stake in shares of Natera by 2.2% in the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after purchasing an additional 72,087 shares during the last quarter. Franklin Resources Inc. boosted its stake in shares of Natera by 37.5% in the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after purchasing an additional 727,366 shares during the last quarter. Finally, Coatue Management LLC boosted its stake in shares of Natera by 1,446.1% in the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after purchasing an additional 2,463,008 shares during the last quarter. 99.90% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
NTRA has been the topic of a number of research reports. Canaccord Genuity Group reissued a “buy” rating on shares of Natera in a report on Monday, January 12th. TD Cowen reissued a “buy” rating on shares of Natera in a report on Wednesday, January 7th. Zacks Research raised shares of Natera from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Morgan Stanley reduced their target price on shares of Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. Finally, Wells Fargo & Company upped their price objective on shares of Natera from $205.00 to $215.00 and gave the company an “equal weight” rating in a research note on Friday, February 27th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $253.47.
View Our Latest Stock Report on NTRA
Natera Company Profile
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
See Also
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
